Safety Assessment of a Novel Neonatal Ventilator Circuit Patient Interface Connector for the Delivery of Aerosolized Medication to Mechanically Ventilated Infants –
Respiratory Therapy. February-
March 2013, Vol. 8, No. 1, Pages 29-33
As part of a safety assessment of AFECTAIR, studies were conducted to determine the dead space volume (volume of gas that remains in device, undelivered to the patient), the resistance to gas flows through AFECTAIR relative to a standard configuration, as well as the interaction between the ventilator circuit gas and the aerosol carrier gas using the two configurations. Authors concluded that, when used correctly, AFECTAIR has a comparable safety profile to standard wye connectors and aerosol delivery configurations. Authors also stated that further studies are needed to determine the impact of AFECTAIR on the delivery of aerosolized medications to mechanically ventilated infants.
Use of AFECTAIR may result in an increase in the delivery of aerosolized medication to patients receiving mechanical ventilation. When delivering aerosolized medication through AFECTAIR to patients receiving mechanical ventilation, a qualified healthcare personnel should closely monitor the response to the aerosolized medication.
About Journal of Aerosol Medicine and Pulmonary Drug Delivery
The Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only authoritative journal delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient.About Respiratory Therapy Respiratory Therapy, the Journal of Pulmonary Technique, brings a new concept in presenting information to respiratory therapy managers and supervisors, respiratory therapists, nurses, researchers and students with the goal of presenting a wide variety of papers in a clear, effective and familiar clinical format. Respiratory Therapy's international clinical focus ensures readers receive, with every issue, the latest and best information about all aspects of respiratory therapy as actively practiced in a wide variety of clinical venues and modalities. About Discovery Labs Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV